Please login to the form below

Not currently logged in
Email:
Password:

SMC decides Celgene's Imnovid is not cost-effective

Scottish cancer patients denied access to the cancer drug
Scotland flag

People in Scotland with the blood cancer multiple myeloma should not have access to Celgene's Imnovid at its current price, according to the Scottish Medicines Consortirum (SMC).

The decision was published in the latest round-up of decisions from the SMC, which provides guidance on medicines for use with NHS Scotland. Drugs that received backing included Sanofi's Lemtrada for multiple sclerosis (MS), a subcutaneous formulation of Roche's Mabthera and AstraZeneca's Forxiga for type 2 diabetes.

The same could not be said for Imnovid (pomalidomide), which is approved in Europe in combination with dexamethasone for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens.

In its statement, the SMC acknowledged that Imnovid plus dexamethasone “significantly increased progression-free survival compared with high-dose dexamethasone” in this group of patients, but it also said data presented by Celgene did not justify the treatment's cost in relation to its benefit.

Dr Adrian Kilcoyne, medical director at Celgene UK & Ireland, said: “We are obviously disappointed with today's decision especially since the SMC acknowledged that pomalidomide substantially improved the life expectancy of patients with relapsed and refractory multiple myeloma.

“We will of course do everything we can to try and ensure that patients in Scotland are able to access the treatment and have therefore already re-entered into discussions with the SMC,” he added.

SMC recommendations

There was positive news for other patients, however, as the SMC recommended several other new treatments.

These included Lemtrada (alemtuzumab), an MS treatment developed by Genzyme, part of Sanofi. The SMC recommended the drug's use for the relapsing remitting form of MS based on studies where Lemtrada demonstrated a statistically significant relative decrease in relapse rate compared to current treatment Rebif (interferon beta 1a).

The SMC also recommended UCB's Cimzia in patients with active psoriatic arthritis, although its use is restricted to adults who have inadequate response to treatment with a disease-modifying antirheumatic drug (DMARD).

AZ's Forxiga was recommended at the second attempt for use in adults with type 2 diabetes as an add-on combination therapy while it was also good news for Roche, which had a subcutaneous version of Mabthera (rituximab) recommended for use in certain patients with non-Hodgkin's lymphoma.

There was also a positive decision on Allergan's Botox (botulinum toxin type A) for use in the management of bladder dysfunctions.

Article by
Thomas Meek

9th July 2014

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
90TEN

90TEN is an award-winning healthcare communications consultancy that puts people at the heart of everything we do. Our Life.Changing. campaigns...

Latest intelligence

The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
real world studies
The evolution of real-world studies
How industry and regulators are using real-world data...

Infographics